Clinical Trial Update: Rituximab and RASi in Patients with IgAN [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating rituximab plus renin-angiotensin system inhibitors in patients with IgA nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• RAS inhibitors (renin-angiotensin system inhibitors)
• Rituximab (rituximab)

Snippet

Sponsor: Nan Chen,MD | Conditions: IgA Nephropathy | Phase 4 | Status: COMPLETED